Anticoagulants, antiplatelets, and thrombolytics
Author(s)
Bibliographic Information
Anticoagulants, antiplatelets, and thrombolytics
(Methods in molecular medicine / John M. Walker, series editor, 93)
Humana Press, c2004
Available at 3 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Description and Table of Contents
Description
This collection of review articles highlights the latest development of antithrombotics and provides proven experimental methods for the further development of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as the hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue factor targeting, platelet receptor targeting, and antithrombin III modulation.
Table of Contents
Highlights of Latest Advances in Antithrombotics Shaker A. Mousa Antiplatelet, Anticoagulant, and Thrombolytic Drug Interactions Omer Iqbal and Shaker A. Mousa Evaluation of Platelet Antagonists in In Vitro Flow Models of Thrombosis Owen J. T. McCarty, James P. Abulencia, Shaker A. Mousa, and Konstantinos Konstantopoulos Heparin and Low Molecular Weight Heparin in Thrombosis, Cancer, and Inflammatory Diseases Shaker A. Mousa Are Low Molecular Weight Heparins the Same? Shaker A. Mousa Antithrombotic Drugs for the Treatment of Heparin-Induced Thrombocytopenia Walter P. Jeske and Jeanine M. Walenga Laboratory Methods for Heparin-Induced Thrombocytopenia Margaret Prechel, Walter P. Jeske, and Jeanine M. Walenga Factor Xa Inhibitors Jeanine M. Walenga, Walter P. Jeske, Debra Hoppensteadt, and Jawed Fareed Tissue Factor/VIIa in Thrombosis and Cancer Shaker A. Mousa Tissue Factor Pathway Inhibitor in Thrombosis and Beyond Shaker A. Mousa, Jawed Fareed, Omer Iqbal, and Brigitte Kaiser Cell Adhesion Molecules: Potential Therapeutic and Diagnostic Implications Shaker A. Mousa Development and Applications of Animal Models of Thrombosis Ronald J. Shebuski, Larry R. Bush, Alison Gagnon, Liguo Chi, and Robert J. Leadley, Jr. A Survey of Venous Thrombosis Models Walter P. Jeske, Omer Iqbal, Jawed Fareed, and Brigitte Kaiser Arixtra(R) (Fondaparinux Sodium) Shaker A. Mousa Oral Thrombin Inhibitor Ximelagatran Shaker A. Mousa Pharmacogenomics and Coagulation Disorders Omer Iqbal Guidelines for Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Hikmat Abdel-Razeq, Mohamad Qari, Jorgen Kristensen, Hussein Alizeidah, Faisal Al-Sayegh, Mahmoud Marashi, Abdulaziz Alzeer, Omar Al-Amoudi, Hatem Qutub, Abdel-Aziz Al-Humiadi, Steen Husted, and Shaker A. Mousa on behalf of the GCC Thrombosis Study Group Index
by "Nielsen BookData"